Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed Informed Consent Form
Metastatic or locally advanced and unresectable colorectal cancer
Measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST)
Age \>= 18 years
ECOG performance status of 0 or 1
Adequate hematologic, hepatic, and renal function at the time of study entry to begin prescribed study therapy, according to institutional guidelines
Use of an effective form of contraception during the study (for subjects of childbearing potential and their partners)
You may not be if
Prior treatment with Avastin
Hypersensitivity to any of the study drugs or ingredients
Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored Avastin cancer study
History of any other malignancy (except squamous or basal cell carcinoma of the skin, carcinoma in situ of the cervix, or carcinoma in situ of the colon or rectum that has been effectively treated) unless in complete remission and off all therapy for that malignancy for at least 5 years
Known brain or central nervous system metastases
Prior treatment for advanced or metastatic colorectal cancer
Prior treatment with an anti-angiogenesis agent, in either the adjuvant or metastatic setting
Concurrent use of investigational anti-neoplastic agents (including up to 4 weeks prior to enrollment)
Medical or psychiatric disorders that would interfere with informed consent or compliance, or would render the subject at high risk for participation in this study and its follow-up procedures
Active infection requiring antibiotics on Day 1
New York Heart Association (NYHA) Grade II or greater CHF
Evidence of bleeding diathesis or coagulopathy
Grade \> 1 peripheral neuropathy (as defined by the NCI CTCAE, v3.0)
Lack of physical integrity of the upper gastrointestinal tract or history of malabsorption syndrome
Blood pressure \> 150/100 mmHg
Major surgical procedure, open biopsy, or significant traumatic injury within 30 days prior to Day 1; anticipation of need for a major surgical procedure during the course of the study
Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to Day 1
Urine protein:creatinine ratio \>= 1.0 at screening
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 1
Serious, non-healing wound, ulcer, or bone fracture
History of myocardial infarction within 6 months prior to Day 1
